James Marks, MD, PhD

Professor
Publications: 
Sachdev DD, Petersen M, Havlir DV, Schwab J, Enanoria WTA, Nguyen TQ, Mercer MP, Scheer S, Bennett A, Tenner AG, Marks JD, Bobba N, Philip S, Colfax G. San Francisco's Citywide COVID-19 Response: Strategies to Reduce COVID-19 Severity and Health Disparities, March 2020 Through May 2022. Public Health Rep. 2023 Sep-Oct; 138(5):747-755.
Fan Y, Lou J, Tam CC, Wen W, Conrad F, Leal da Silva Alves P, Cheng LW, Garcia-Rodriguez C, Farr-Jones S, Marks JD. A Three-Monoclonal Antibody Combination Potently Neutralizes BoNT/G Toxin in Mice. Toxins (Basel). 2023 04 30; 15(5).
Fan Y, Sun Z, Conrad F, Wen W, Zhao L, Lou J, Zhou Y, Farr-Jones S, Marks JD. Multicolor fluorescence activated cell sorting to generate humanized monoclonal antibody binding seven subtypes of BoNT/F. PLoS One. 2022; 17(9):e0273512.
Tomic MT, Farr-Jones S, Syar ES, Niemuth N, Kobs D, Hackett MJ, Espinoza Y, Martinez Z, Pham K, Snow DM, Marks JD, Cobb RR. Neutralizing Concentrations of Anti-Botulinum Toxin Antibodies Positively Correlate with Mouse Neutralization Assay Results in a Guinea Pig Model. Toxins (Basel). 2021 09 21; 13(9).
Garcia-Rodriguez C, Yan S, Geren IN, Knopp KA, Dong J, Sun Z, Lou J, Conrad F, Wen WH, Farr-Jones S, Smith TJ, Brown JL, Skerry JC, Smith LA, Marks JD. A Four-Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotypes C and D. Toxins (Basel). 2021 09 10; 13(9).
Snow DM, Cobb RR, Martinez J, Finger-Baker I, Collins L, Terpening S, Syar ES, Niemuth N, Kobs D, Barnewall R, Farr-Jones S, Marks JD, Tomic MT. A Monoclonal Antibody Combination against both Serotypes A and B Botulinum Toxin Prevents Inhalational Botulism in a Guinea Pig Model. Toxins (Basel). 2021 01 05; 13(1).
Kamoun W, Swindell E, Pien C, Luus L, Cain J, Pham M, Kandela I, Huang ZR, Tipparaju SK, Koshkaryev A, Askoxylakis V, Kirpotin DB, Bloom T, Mino-Kenudson M, Marks JD, Zalutskaya A, Bshara W, Morrison C, Drummond DC. Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic. Pharmaceutics. 2020 Oct 20; 12(10).
Campbell MG, Cormier A, Ito S, Seed RI, Bondesson AJ, Lou J, Marks JD, Baron JL, Cheng Y, Nishimura SL. Cryo-EM Reveals Integrin-Mediated TGF-β Activation without Release from Latent TGF-β. Cell. 2020 02 06; 180(3):490-501.e16.
Fan Y, Barash JR, Conrad F, Lou J, Tam C, Cheng LW, Arnon SS, Marks JD. The Novel Clostridial Neurotoxin Produced by Strain IBCA10-7060 Is Immunologically Equivalent to BoNT/HA. Toxins (Basel). 2019 12 20; 12(1).
Tam EM, Fulton RB, Sampson JF, Muda M, Camblin A, Richards J, Koshkaryev A, Tang J, Kurella V, Jiao Y, Xu L, Zhang K, Kohli N, Luus L, Hutto E, Kumar S, Lulo J, Paragas V, Wong C, Suchy J, Grabow S, Dugast AS, Zhang H, Depis F, Feau S, Jakubowski A, Qiao W, Craig G, Razlog M, Qiu J, Zhou Y, Marks JD, Croft M, Drummond DC, Raue A. Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity. Sci Transl Med. 2019 10 02; 11(512).
Snow DM, Riling K, Kimbler A, Espinoza Y, Wong D, Pham K, Martinez Z, Kraus CN, Conrad F, Garcia-Rodriguez C, Cobb RR, Marks JD, Tomic MT. Safety and Pharmacokinetics of a Four Monoclonal Antibody Combination Against Botulinum C and D Neurotoxins. Antimicrob Agents Chemother. 2019 09 09; 63(12).
Espinoza Y, Wong D, Ahene A, Der K, Martinez Z, Pham J, Cobb RR, Farr-Jones S, Marks JD, Tomic MT. Pharmacokinetics of Human Recombinant Anti-Botulinum Toxin Antibodies in Rats. Toxins (Basel). 2019 06 17; 11(6).
Tomic MT, Espinoza Y, Martinez Z, Pham K, Cobb RR, Snow DM, Earnhart CG, Pals T, Syar ES, Niemuth N, Kobs DJ, Farr-Jones S, Marks JD. Monoclonal Antibody Combinations Prevent Serotype A and Serotype B Inhalational Botulism in a Guinea Pig Model. Toxins (Basel). 2019 04 06; 11(4).
Kamoun WS, Kirpotin DB, Huang ZR, Tipparaju SK, Noble CO, Hayes ME, Luus L, Koshkaryev A, Kim J, Olivier K, Kornaga T, Oyama S, Askoxylakis V, Pien C, Kuesters G, Dumont N, Lugovskoy AA, Schihl SA, Wilton JH, Geddie ML, Suchy J, Grabow S, Kohli N, Reynolds CP, Blaydes R, Zhou Y, Sawyer AJ, Marks JD, Drummond DC. Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models. Nat Biomed Eng. 2019 04; 3(4):264-280.
Lou J, Marks JD. Botulinum Neurotoxins (BoNTs)-Antibody and Vaccine. Toxins (Basel). 2018 11 26; 10(12).
Takasaka N, Seed RI, Cormier A, Bondesson AJ, Lou J, Elattma A, Ito S, Yanagisawa H, Hashimoto M, Ma R, Levine MD, Publicover J, Potts R, Jespersen JM, Campbell MG, Conrad F, Marks JD, Cheng Y, Baron JL, Nishimura SL. Integrin αvβ8-expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells. JCI Insight. 2018 10 18; 3(20).
Wijesuriya SD, Pongo E, Tomic M, Zhang F, Garcia-Rodriquez C, Conrad F, Farr-Jones S, Marks JD, Horwitz AH. Antibody engineering to improve manufacturability. Protein Expr Purif. 2018 09; 149:75-83.
Garcia-Rodriguez C, Razai A, Geren IN, Lou J, Conrad F, Wen WH, Farr-Jones S, Smith TJ, Brown JL, Skerry JC, Smith LA, Marks JD. A Three Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotype E Subtypes. Toxins (Basel). 2018 03 01; 10(3).
Lou J, Wen W, Conrad F, Meng Q, Dong J, Sun Z, Garcia-Rodriguez C, Farr-Jones S, Cheng LW, Henderson TD, Brown JL, Smith TJ, Smith LA, Cormier A, Marks JD. A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of Three Monoclonal Antibodies in Neutralization of Botulinum Neurotoxin Serotype A. Toxins (Basel). 2018 02 15; 10(2).
Zhou Y, Zou H, Yau C, Zhao L, Hall SC, Drummond DC, Farr-Jones S, Park JW, Benz CC, Marks JD. Discovery of internalizing antibodies to basal breast cancer cells. Protein Eng Des Sel. 2018 01 01; 31(1):17-28.
Fan Y, Garcia-Rodriguez C, Lou J, Wen W, Conrad F, Zhai W, Smith TJ, Smith LA, Marks JD. A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype F subtypes. PLoS One. 2017; 12(3):e0174187.
Geddie ML, Kohli N, Kirpotin DB, Razlog M, Jiao Y, Kornaga T, Rennard R, Xu L, Schoerberl B, Marks JD, Drummond DC, Lugovskoy AA. Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting. MAbs. 2017 01; 9(1):58-67.
Peyton C, Yang E, Msall ME, Adde L, Støen R, Fjørtoft T, Bos AF, Einspieler C, Zhou Y, Schreiber MD, Marks JD, Drobyshevsky A. White Matter Injury and General Movements in High-Risk Preterm Infants. AJNR Am J Neuroradiol. 2017 Jan; 38(1):162-169.
Fan Y, Barash JR, Lou J, Conrad F, Marks JD, Arnon SS. Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H. J Infect Dis. 2016 May 15; 213(10):1606-14.
Krombach JW, Marks JD, Dubowitz G, Radke OC. Development and Implementation of Checklists for Routine Anesthesia Care: A Proposal for Improving Patient Safety. Anesth Analg. 2015 Oct; 121(4):1097-1103.
Le Gall M, Crépin R, Neiveyans M, Auclair C, Fan Y, Zhou Y, Marks JD, Pèlegrin A, Poul MA. Neutralization of KIT Oncogenic Signaling in Leukemia with Antibodies Targeting KIT Membrane Proximal Domain 5. Mol Cancer Ther. 2015 Nov; 14(11):2595-605.
Fan Y, Dong J, Lou J, Wen W, Conrad F, Geren IN, Garcia-Rodriguez C, Smith TJ, Smith LA, Ho M, Pires-Alves M, Wilson BA, Marks JD. Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B. Toxins (Basel). 2015 Aug 26; 7(9):3405-23.
Krombach JW, Edwards WA, Marks JD, Radke OC. Checklists and Other Cognitive Aids For Emergency And Routine Anesthesia Care-A Survey on the Perception of Anesthesia Providers From a Large Academic US Institution. Anesth Pain Med. 2015 Aug; 5(4):e26300.
Seldon TA, Pryor R, Palkova A, Jones ML, Verma ND, Findova M, Braet K, Sheng Y, Fan Y, Zhou EY, Marks JD, Munro T, Mahler SM, Barnard RT, Fromm PD, Silveira PA, Elgundi Z, Ju X, Clark GJ, Bradstock KF, Munster DJ, Hart DN. Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation. Leukemia. 2016 Mar; 30(3):692-700.
Fan Y, Geren IN, Dong J, Lou J, Wen W, Conrad F, Smith TJ, Smith LA, Ho M, Pires-Alves M, Wilson BA, Marks JD. Monoclonal Antibodies Targeting the Alpha-Exosite of Botulinum Neurotoxin Serotype/A Inhibit Catalytic Activity. PLoS One. 2015; 10(8):e0135306.
Hashimoto M, Yanagisawa H, Minagawa S, Sen D, Ma R, Murray LA, Tsui P, Lou J, Marks JD, Baron JL, Krummel MF, Nishimura SL. TGF-β-Dependent Dendritic Cell Chemokinesis in Murine Models of Airway Disease. J Immunol. 2015 Aug 01; 195(3):1182-90.
Li K, Zettlitz KA, Lipianskaya J, Zhou Y, Marks JD, Mallick P, Reiter RE, Wu AM. A fully human scFv phage display library for rapid antibody fragment reformatting. Protein Eng Des Sel. 2015 Oct; 28(10):307-16.
Brand OJ, Somanath S, Moermans C, Yanagisawa H, Hashimoto M, Cambier S, Markovics J, Bondesson AJ, Hill A, Jablons D, Wolters P, Lou J, Marks JD, Baron JL, Nishimura SL. Transforming Growth Factor-β and Interleukin-1β Signaling Pathways Converge on the Chemokine CCL20 Promoter. J Biol Chem. 2015 Jun 05; 290(23):14717-28.
D'Souza JW, Reddy S, Goldsmith LE, Shchaveleva I, Marks JD, Litwin S, Robinson MK. Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies. PLoS One. 2014; 9(11):e112376.
Zhao L, Qu L, Zhou J, Sun Z, Zou H, Chen YY, Marks JD, Zhou Y. High throughput identification of monoclonal antibodies to membrane bound and secreted proteins using yeast and phage display. PLoS One. 2014; 9(10):e111339.
Li K, Tavaré R, Zettlitz KA, Mumenthaler SM, Mallick P, Zhou Y, Marks JD, Wu AM. Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments. Mol Cancer Ther. 2014 Nov; 13(11):2607-17.
Jenko KL, Zhang Y, Kostenko Y, Fan Y, Garcia-Rodriguez C, Lou J, Marks JD, Varnum SM. Development of an ELISA microarray assay for the sensitive and simultaneous detection of ten biodefense toxins. Analyst. 2014 Oct 21; 139(20):5093-102.
Tavaré R, Wu WH, Zettlitz KA, Salazar FB, McCabe KE, Marks JD, Wu AM. Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific ⁶⁴Cu-DOTA conjugation. Protein Eng Des Sel. 2014 Oct; 27(10):317-24.
Minagawa S, Lou J, Seed RI, Cormier A, Wu S, Cheng Y, Murray L, Tsui P, Connor J, Herbst R, Govaerts C, Barker T, Cambier S, Yanagisawa H, Goodsell A, Hashimoto M, Brand OJ, Cheng R, Ma R, McKnelly KJ, Wen W, Hill A, Jablons D, Wolters P, Kitamura H, Araya J, Barczak AJ, Erle DJ, Reichardt LF, Marks JD, Baron JL, Nishimura SL. Selective targeting of TGF-β activation to treat fibroinflammatory airway disease. Sci Transl Med. 2014 Jun 18; 6(241):241ra79.
Jones AR, Stutz CC, Zhou Y, Marks JD, Shusta EV. Identifying blood-brain-barrier selective single-chain antibody fragments. Biotechnol J. 2014 May; 9(5):664-74.
Strotmeier J, Mahrhold S, Krez N, Janzen C, Lou J, Marks JD, Binz T, Rummel A. Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A. FEBS Lett. 2014 Apr 02; 588(7):1087-93.
Janardhanan P, Mello CM, Singh BR, Lou J, Marks JD, Cai S. RNA aptasensor for rapid detection of natively folded type A botulinum neurotoxin. Talanta. 2013 Dec 15; 117:273-80.
Mahrhold S, Strotmeier J, Garcia-Rodriguez C, Lou J, Marks JD, Rummel A, Binz T. Identification of the SV2 protein receptor-binding site of botulinum neurotoxin type E. Biochem J. 2013 Jul 01; 453(1):37-47.
Jones RGA, Marks JD. Use of a new functional dual coating (FDC) assay to measure low toxin levels in serum and food samples following an outbreak of human botulism. J Med Microbiol. 2013 Jun; 62(Pt 6):828-835.
Federman N, Chan J, Nagy JO, Landaw EM, McCabe K, Wu AM, Triche T, Kang H, Liu B, Marks JD, Denny CT. Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the alcam cell surface receptor. Sarcoma. 2012; 2012:126906.
Zhang Y, Lou J, Jenko KL, Marks JD, Varnum SM. Simultaneous and sensitive detection of six serotypes of botulinum neurotoxin using enzyme-linked immunosorbent assay-based protein antibody microarrays. Anal Biochem. 2012 Nov 15; 430(2):185-92.
Meng Q, Garcia-Rodriguez C, Manzanarez G, Silberg MA, Conrad F, Bettencourt J, Pan X, Breece T, To R, Li M, Lee D, Thorner L, Tomic MT, Marks JD. Engineered domain-based assays to identify individual antibodies in oligoclonal combinations targeting the same protein. Anal Biochem. 2012 Nov 15; 430(2):141-50.
Carrico ZM, Farkas ME, Zhou Y, Hsiao SC, Marks JD, Chokhawala H, Clark DS, Francis MB. N-Terminal labeling of filamentous phage to create cancer marker imaging agents. ACS Nano. 2012 Aug 28; 6(8):6675-80.
McCabe KE, Liu B, Marks JD, Tomlinson JS, Wu H, Wu AM. An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors. Mol Imaging Biol. 2012 Jun; 14(3):336-47.
Zhou Y, Zhao L, Marks JD. Selection and characterization of cell binding and internalizing phage antibodies. Arch Biochem Biophys. 2012 Oct 15; 526(2):107-13.
Zhou Y, Goenaga AL, Harms BD, Zou H, Lou J, Conrad F, Adams GP, Schoeberl B, Nielsen UB, Marks JD. Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies. Mol Cancer Ther. 2012 Jul; 11(7):1467-76.
Liu YY, Rigsby P, Sesardic D, Marks JD, Jones RG. A functional dual-coated (FDC) microtiter plate method to replace the botulinum toxin LD50 test. Anal Biochem. 2012 Jun 01; 425(1):28-35.
Kirpotin DB, Noble CO, Hayes ME, Huang Z, Kornaga T, Zhou Y, Nielsen UB, Marks JD, Drummond DC. Building and characterizing antibody-targeted lipidic nanotherapeutics. Methods Enzymol. 2012; 502:139-66.
Zhou Y, Marks JD. Discovery of internalizing antibodies to tumor antigens from phage libraries. Methods Enzymol. 2012; 502:43-66.
Cao Y, Marks JD, Huang Q, Rudnick SI, Xiong C, Hittelman WN, Wen X, Marks JW, Cheung LH, Boland K, Li C, Adams GP, Rosenblum MG. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity. Mol Cancer Ther. 2012 Jan; 11(1):143-53.
Kalb SR, Santana WI, Geren IN, Garcia-Rodriguez C, Lou J, Smith TJ, Marks JD, Smith LA, Pirkle JL, Barr JR. Extraction and inhibition of enzymatic activity of botulinum neurotoxins /B1, /B2, /B3, /B4, and /B5 by a panel of monoclonal anti-BoNT/B antibodies. BMC Biochem. 2011 Nov 15; 12:58.
Wang Y, Keck ZY, Saha A, Xia J, Conrad F, Lou J, Eckart M, Marks JD, Foung SKH. Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus. J Biol Chem. 2011 Dec 23; 286(51):44218-44233.
Meng Q, Li M, Silberg MA, Conrad F, Bettencourt J, To R, Huang C, Ma J, Meyer K, Shimizu R, Cao L, Tomic MT, Marks JD. Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein. Anal Biochem. 2012 Feb 15; 421(2):351-61.
Kitamura H, Cambier S, Somanath S, Barker T, Minagawa S, Markovics J, Goodsell A, Publicover J, Reichardt L, Jablons D, Wolters P, Hill A, Marks JD, Lou J, Pittet JF, Gauldie J, Baron JL, Nishimura SL. Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin αvβ8-mediated activation of TGF-β. J Clin Invest. 2011 Jul; 121(7):2863-75.
Gray SA, Barr JR, Kalb SR, Marks JD, Baird CL, Cangelosi GA, Miller KD, Feldhaus MJ. Synergistic capture of Clostridium botulinum type A neurotoxin by scFv antibodies to novel epitopes. Biotechnol Bioeng. 2011 Oct; 108(10):2456-67.
Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, Marks JD, Adams GP. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res. 2011 Mar 15; 71(6):2250-9.
Reddy S, Shaller CC, Doss M, Shchaveleva I, Marks JD, Yu JQ, Robinson MK. Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment. Clin Cancer Res. 2011 Mar 15; 17(6):1509-20.
Garcia-Rodriguez C, Geren IN, Lou J, Conrad F, Forsyth C, Wen W, Chakraborti S, Zao H, Manzanarez G, Smith TJ, Brown J, Tepp WH, Liu N, Wijesuriya S, Tomic MT, Johnson EA, Smith LA, Marks JD. Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. Protein Eng Des Sel. 2011 Mar; 24(3):321-31.
Zhou Y, Zou H, Zhang S, Marks JD. Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast-displayed tumor antigens. J Mol Biol. 2010 Nov 19; 404(1):88-99.
Kalb SR, Garcia-Rodriguez C, Lou J, Baudys J, Smith TJ, Marks JD, Smith LA, Pirkle JL, Barr JR. Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS. PLoS One. 2010 Aug 17; 5(8):e12237.
Diaz L, Mao H, Zhou Y, Kohli M, Cassella J, Santos D, Fesseha Z, Weng K, Chen H, Bamba D, Marks JD, Goldblatt M, Kinch M. TSG101 exposure on the surface of HIV-1 infected cells: implications for monoclonal antibody therapy for HIV/AIDS. Am J Transl Res. 2010 Jul 20; 2(4):368-80.
Crépin R, Goenaga AL, Jullienne B, Bougherara H, Legay C, Benihoud K, Marks JD, Poul MA. Development of human single-chain antibodies to the transferrin receptor that effectively antagonize the growth of leukemias and lymphomas. Cancer Res. 2010 Jul 01; 70(13):5497-506.
Lepin EJ, Leyton JV, Zhou Y, Olafsen T, Salazar FB, McCabe KE, Hahm S, Marks JD, Reiter RE, Wu AM. An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur J Nucl Med Mol Imaging. 2010 Aug; 37(8):1529-38.
Lou J, Geren I, Garcia-Rodriguez C, Forsyth CM, Wen W, Knopp K, Brown J, Smith T, Smith LA, Marks JD. Affinity maturation of human botulinum neurotoxin antibodies by light chain shuffling via yeast mating. Protein Eng Des Sel. 2010 Apr; 23(4):311-9.
Darragh MR, Schneider EL, Lou J, Phojanakong PJ, Farady CJ, Marks JD, Hann BC, Craik CS. Tumor detection by imaging proteolytic activity. Cancer Res. 2010 Feb 15; 70(4):1505-12.
Dong J, Thompson AA, Fan Y, Lou J, Conrad F, Ho M, Pires-Alves M, Wilson BA, Stevens RC, Marks JD. A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. J Mol Biol. 2010 Apr 09; 397(4):1106-18.
Cao Y, Marks JD, Marks JW, Cheung LH, Kim S, Rosenblum MG. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies. Cancer Res. 2009 Dec 01; 69(23):8987-95.
Drummond DC, Noble CO, Guo Z, Hayes ME, Connolly-Ingram C, Gabriel BS, Hann B, Liu B, Park JW, Hong K, Benz CC, Marks JD, Kirpotin DB. Development of a highly stable and targetable nanoliposomal formulation of topotecan. J Control Release. 2010 Jan 04; 141(1):13-21.
Cheng LW, Stanker LH, Henderson TD, Lou J, Marks JD. Antibody protection against botulinum neurotoxin intoxication in mice. Infect Immun. 2009 Oct; 77(10):4305-13.
Ozanich RM, Bruckner-Lea CJ, Warner MG, Miller K, Antolick KC, Marks JD, Lou J, Grate JW. Rapid multiplexed flow cytometric assay for botulinum neurotoxin detection using an automated fluidic microbead-trapping flow cell for enhanced sensitivity. Anal Chem. 2009 Jul 15; 81(14):5783-93.
Warner MG, Grate JW, Tyler A, Ozanich RM, Miller KD, Lou J, Marks JD, Bruckner-Lea CJ. Quantum dot immunoassays in renewable surface column and 96-well plate formats for the fluorescence detection of botulinum neurotoxin using high-affinity antibodies. Biosens Bioelectron. 2009 Sep 15; 25(1):179-84.
Kalb SR, Lou J, Garcia-Rodriguez C, Geren IN, Smith TJ, Moura H, Marks JD, Smith LA, Pirkle JL, Barr JR. Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies. PLoS One. 2009; 4(4):e5355.
Grate JW, Warner MG, Ozanich RM, Miller KD, Colburn HA, Dockendorff B, Antolick KC, Anheier NC, Lind MA, Lou J, Marks JD, Bruckner-Lea CJ. Renewable surface fluorescence sandwich immunoassay biosensor for rapid sensitive botulinum toxin detection in an automated fluidic format. Analyst. 2009 May; 134(5):987-96.
Conrad F, Zhu X, Zhang X, Chalkley RJ, Burlingame AL, Marks JD, Liu B. Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion. J Mol Med (Berl). 2009 May; 87(5):507-14.
Noble CO, Guo Z, Hayes ME, Marks JD, Park JW, Benz CC, Kirpotin DB, Drummond DC. Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. Cancer Chemother Pharmacol. 2009 Sep; 64(4):741-51.
Zhou Y, Marks JD. Identification of target and function specific antibodies for effective drug delivery. Methods Mol Biol. 2009; 525:145-60, xv.
Dimitrov DS, Marks JD. Therapeutic antibodies: current state and future trends--is a paradigm change coming soon? Methods Mol Biol. 2009; 525:1-27, xiii.
Shimazaki K, Lepin EJ, Wei B, Nagy AK, Coulam CP, Mareninov S, Fu M, Wu AM, Marks JD, Braun J, Gordon LK, Wadehra M. Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines. Clin Cancer Res. 2008 Nov 15; 14(22):7367-77.
Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, von Mehren M, Shchaveleva I, Simmons HH, Marks JD, Adams GP. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer. 2008 Nov 04; 99(9):1415-25.
Leung KM, Feng DX, Lou J, Zhou Y, Fung KP, Waye MM, Tsui SK, Chan PK, Marks JD, Pang SF, Kan YW. Development of human single-chain antibodies against SARS-associated coronavirus. Intervirology. 2008; 51(3):173-81.
Robinson MK, Shaller C, Garmestani K, Plascjak PS, Hodge KM, Yuan QA, Marks JD, Waldmann TA, Brechbiel MW, Adams GP. Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin Cancer Res. 2008 Feb 01; 14(3):875-82.
Smith TJ, Hill KK, Foley BT, Detter JC, Munk AC, Bruce DC, Doggett NA, Smith LA, Marks JD, Xie G, Brettin TS. Analysis of the neurotoxin complex genes in Clostridium botulinum A1-A4 and B1 strains: BoNT/A3, /Ba4 and /B1 clusters are located within plasmids. PLoS One. 2007 Dec 05; 2(12):e1271.
Fischer A, Garcia-Rodriguez C, Geren I, Lou J, Marks JD, Nakagawa T, Montal M. Molecular architecture of botulinum neurotoxin E revealed by single particle electron microscopy. J Biol Chem. 2008 Feb 15; 283(7):3997-4003.
Roth A, Drummond DC, Conrad F, Hayes ME, Kirpotin DB, Benz CC, Marks JD, Liu B. Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther. 2007 Oct; 6(10):2737-46.
Turatti F, Figini M, Balladore E, Alberti P, Casalini P, Marks JD, Canevari S, Mezzanzanica D. Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction. J Immunother. 2007 Oct; 30(7):684-93.
Hasegawa K, Hu C, Nakamura T, Marks JD, Russell SJ, Peng KW. Affinity thresholds for membrane fusion triggering by viral glycoproteins. J Virol. 2007 Dec; 81(23):13149-57.
Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM. Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol. 2007 Sep 01; 179(5):2815-23.
Liu B, Conrad F, Roth A, Drummond DC, Simko JP, Marks JD. Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer. J Mol Med (Berl). 2007 Oct; 85(10):1113-23.
Goenaga AL, Zhou Y, Legay C, Bougherara H, Huang L, Liu B, Drummond DC, Kirpotin DB, Auclair C, Marks JD, Poul MA. Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies. Mol Immunol. 2007 Jul; 44(15):3777-88.
Zhou Y, Drummond DC, Zou H, Hayes ME, Adams GP, Kirpotin DB, Marks JD. Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J Mol Biol. 2007 Aug 24; 371(4):934-47.
Garcia-Rodriguez C, Levy R, Arndt JW, Forsyth CM, Razai A, Lou J, Geren I, Stevens RC, Marks JD. Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol. 2007 Jan; 25(1):107-16.
Hill KK, Smith TJ, Helma CH, Ticknor LO, Foley BT, Svensson RT, Brown JL, Johnson EA, Smith LA, Okinaka RT, Jackson PJ, Marks JD. Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J Bacteriol. 2007 Feb; 189(3):818-32.
Hayes ME, Drummond DC, Hong K, Zheng WW, Khorosheva VA, Cohen JA, C O N, Park JW, Marks JD, Benz CC, Kirpotin DB. Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation. Mol Pharm. 2006 Nov-Dec; 3(6):726-36.
Levy R, Forsyth CM, LaPorte SL, Geren IN, Smith LA, Marks JD. Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. J Mol Biol. 2007 Jan 05; 365(1):196-210.
Nielsen UB, Kirpotin DB, Pickering EM, Drummond DC, Marks JD. A novel assay for monitoring internalization of nanocarrier coupled antibodies. BMC Immunol. 2006 Oct 02; 7:24.
Kehoe JW, Velappan N, Walbolt M, Rasmussen J, King D, Lou J, Knopp K, Pavlik P, Marks JD, Bertozzi CR, Bradbury AR. Using phage display to select antibodies recognizing post-translational modifications independently of sequence context. Mol Cell Proteomics. 2006 Dec; 5(12):2350-63.
Arndt JW, Jacobson MJ, Abola EE, Forsyth CM, Tepp WH, Marks JD, Johnson EA, Stevens RC. A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J Mol Biol. 2006 Sep 29; 362(4):733-42.
Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006 Jul 01; 66(13):6732-40.
Varnum SM, Warner MG, Dockendorff B, Anheier NC, Lou J, Marks JD, Smith LA, Feldhaus MJ, Grate JW, Bruckner-Lea CJ. Enzyme-amplified protein microarray and a fluidic renewable surface fluorescence immunoassay for botulinum neurotoxin detection using high-affinity recombinant antibodies. Anal Chim Acta. 2006 Jun 16; 570(2):137-43.
Hayes ME, Drummond DC, Hong K, Park JW, Marks JD, Kirpotin DB. Assembly of nucleic acid-lipid nanoparticles from aqueous-organic monophases. Biochim Biophys Acta. 2006 Apr; 1758(4):429-42.
Hayes ME, Drummond DC, Kirpotin DB, Zheng WW, Noble CO, Park JW, Marks JD, Benz CC, Hong K. Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery. Gene Ther. 2006 Apr; 13(7):646-51.
Adams GP, Tai MS, McCartney JE, Marks JD, Stafford WF, Houston LL, Huston JS, Weiner LM. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res. 2006 Mar 01; 12(5):1599-605.
Horak E, Heitner T, Robinson MK, Simmons HH, Garrison J, Russeva M, Furmanova P, Lou J, Zhou Y, Yuan QA, Weiner LM, Adams GP, Marks JD. Isolation of scFvs to in vitro produced extracellular domains of EGFR family members. Cancer Biother Radiopharm. 2005 Dec; 20(6):603-13.
Smith TJ, Lou J, Geren IN, Forsyth CM, Tsai R, Laporte SL, Tepp WH, Bradshaw M, Johnson EA, Smith LA, Marks JD. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun. 2005 Sep; 73(9):5450-7.
Razai A, Garcia-Rodriguez C, Lou J, Geren IN, Forsyth CM, Robles Y, Tsai R, Smith TJ, Smith LA, Siegel RW, Feldhaus M, Marks JD. Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J Mol Biol. 2005 Aug 05; 351(1):158-69.
Hughes SC, Marks JD. Infectious Disease and Bioterrorism. Anesthesiol Clin North Am. 2004 Sep; 22(3):xiii-xv.
Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, González Trotter DE, Adams GP. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res. 2005 Feb 15; 65(4):1471-8.
Nellis DF, Ekstrom DL, Kirpotin DB, Zhu J, Andersson R, Broadt TL, Ouellette TF, Perkins SC, Roach JM, Drummond DC, Hong K, Marks JD, Park JW, Giardina SL. Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnol Prog. 2005 Jan-Feb; 21(1):205-20.
Nellis DF, Giardina SL, Janini GM, Shenoy SR, Marks JD, Tsai R, Drummond DC, Hong K, Park JW, Ouellette TF, Perkins SC, Kirpotin DB. Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol Prog. 2005 Jan-Feb; 21(1):221-32.
Manoutcharian K, Acero G, Munguia ME, Becerril B, Massieu L, Govezensky T, Ortiz E, Marks JD, Cao C, Ugen K, Gevorkian G. Human single chain Fv antibodies and a complementarity determining region-derived peptide binding to amyloid-beta 1-42. Neurobiol Dis. 2004 Oct; 17(1):114-21.
Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A, Klein-Szanto AJ, Marks JD, Brechbiel MW, Weiner LM. A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res. 2004 Sep 01; 64(17):6200-6.
Marks JD. Medical aspects of biologic toxins. Anesthesiol Clin North Am. 2004 Sep; 22(3):509-32, vii.
Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, Benz CC, Marks JD, Drummond DC. Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets. 2004 Aug; 8(4):335-53.
Bradbury AR, Marks JD. Antibodies from phage antibody libraries. J Immunol Methods. 2004 Jul; 290(1-2):29-49.
Hall YH, Chaddock JA, Moulsdale HJ, Kirby ER, Alexander FC, Marks JD, Foster KA. Novel application of an in vitro technique to the detection and quantification of botulinum neurotoxin antibodies. J Immunol Methods. 2004 May; 288(1-2):55-60.
Weaver-Feldhaus JM, Lou J, Coleman JR, Siegel RW, Marks JD, Feldhaus MJ. Yeast mating for combinatorial Fab library generation and surface display. FEBS Lett. 2004 Apr 23; 564(1-2):24-34.
Marks JD. Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization. Mov Disord. 2004 Mar; 19 Suppl 8:S101-8.
Secco P, Ferretti M, Gioia D, Cesaro P, Bozzo C, Marks JD, Santoro C. Characterization of a single-chain intrabody directed against the human receptor tyrosine kinase Ron. J Immunol Methods. 2004 Feb 01; 285(1):99-109.
Liu B, Conrad F, Cooperberg MR, Kirpotin DB, Marks JD. Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells. Cancer Res. 2004 Jan 15; 64(2):704-10.
Marks JD. Antibody affinity maturation by chain shuffling. Methods Mol Biol. 2004; 248:327-43.
Marks JD, Bradbury A. PCR cloning of human immunoglobulin genes. Methods Mol Biol. 2004; 248:117-34.
Marks JD, Bradbury A. Selection of human antibodies from phage display libraries. Methods Mol Biol. 2004; 248:161-76.
Marks JD. Selection of internalizing antibodies for drug delivery. Methods Mol Biol. 2004; 248:201-8.
Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res. 2003 Jun 15; 63(12):3154-61.
Pavlik P, Siegel RW, Marzari R, Sblattero D, Verzillo V, Collins C, Marks JD, Bradbury A. Predicting antigenic peptides suitable for the selection of phage antibodies. Hum Antibodies. 2003; 12(4):99-112.
O'Connell D, Becerril B, Roy-Burman A, Daws M, Marks JD. Phage versus phagemid libraries for generation of human monoclonal antibodies. J Mol Biol. 2002 Aug 02; 321(1):49-56.
Frank DW, Vallis A, Wiener-Kronish JP, Roy-Burman A, Spack EG, Mullaney BP, Megdoud M, Marks JD, Fritz R, Sawa T. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis. 2002 Jul 01; 186(1):64-73.
Visintin M, Settanni G, Maritan A, Graziosi S, Marks JD, Cattaneo A. The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies. J Mol Biol. 2002 Mar 15; 317(1):73-83.
Amersdorfer P, Wong C, Smith T, Chen S, Deshpande S, Sheridan R, Marks JD. Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine. 2002 Feb 22; 20(11-12):1640-8.
Liu B, Huang L, Sihlbom C, Burlingame A, Marks JD. Towards proteome-wide production of monoclonal antibody by phage display. J Mol Biol. 2002 Feb 01; 315(5):1063-73.
Mullaney BP, Pallavicini MG, Marks JD. Epitope mapping of neutralizing botulinum neurotoxin A antibodies by phage display. Infect Immun. 2001 Oct; 69(10):6511-4.
McCall AM, Shahied L, Amoroso AR, Horak EM, Simmons HH, Nielson U, Adams GP, Schier R, Marks JD, Weiner LM. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. J Immunol. 2001 May 15; 166(10):6112-7.
Sheridan RE, Deshpande SS, Amersdorfer P, Marks JD, Smith T. Anomalous enhancement of botulinum toxin type A neurotoxicity in the presence of antitoxin. Toxicon. 2001 May; 39(5):651-7.
Powers DB, Amersdorfer P, Poul M, Nielsen UB, Shalaby MR, Adams GP, Weiner LM, Marks JD. Expression of single-chain Fv-Fc fusions in Pichia pastoris. J Immunol Methods. 2001 May 01; 251(1-2):123-35.
Huie MA, Cheung MC, Muench MO, Becerril B, Kan YW, Marks JD. Antibodies to human fetal erythroid cells from a nonimmune phage antibody library. Proc Natl Acad Sci U S A. 2001 Feb 27; 98(5):2682-7.
Heitner T, Moor A, Garrison JL, Marks C, Hasan T, Marks JD. Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library. J Immunol Methods. 2001 Feb 01; 248(1-2):17-30.
Neve RM, Nielsen UB, Kirpotin DB, Poul MA, Marks JD, Benz CC. Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function. Biochem Biophys Res Commun. 2001 Jan 12; 280(1):274-9.
Kallet RH, Siobal MS, Alonso JA, Warnecke EL, Katz JA, Marks JD. Lung collapse during low tidal volume ventilation in acute respiratory distress syndrome. Respir Care. 2001 Jan; 46(1):49-52.
Nielsen UB, Adams GP, Weiner LM, Marks JD. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res. 2000 Nov 15; 60(22):6434-40.
Liu B, Marks JD. Applying phage antibodies to proteomics: selecting single chain Fv antibodies to antigens blotted on nitrocellulose. Anal Biochem. 2000 Nov 01; 286(1):119-28.
Siegel RW, Allen B, Pavlik P, Marks JD, Bradbury A. Mass spectral analysis of a protein complex using single-chain antibodies selected on a peptide target: applications to functional genomics. J Mol Biol. 2000 Sep 15; 302(2):285-93.
Kallet RH, Katz JA, Pittet JF, Ghermey J, Siobal M, Alonso JA, Marks JD. Measuring intra-esophageal pressure to assess transmural pulmonary arterial occlusion pressure in patients with acute lung injury: a case series and review. Respir Care. 2000 Sep; 45(9):1072-84.
Poul MA, Becerril B, Nielsen UB, Morisson P, Marks JD. Selection of tumor-specific internalizing human antibodies from phage libraries. J Mol Biol. 2000 Sep 01; 301(5):1149-61.
Adams GP, Shaller CC, Chappell LL, Wu C, Horak EM, Simmons HH, Litwin S, Marks JD, Weiner LM, Brechbiel MW. Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules. Nucl Med Biol. 2000 May; 27(4):339-46.
Kallet RH, Jasmer RM, Luce JM, Lin LH, Marks JD. The treatment of acidosis in acute lung injury with tris-hydroxymethyl aminomethane (THAM). Am J Respir Crit Care Med. 2000 Apr; 161(4 Pt 1):1149-53.
Katz JA, Kallet RH, Alonso JA, Marks JD. Improved flow and pressure capabilities of the Datex-Ohmeda SmartVent anesthesia ventilator. J Clin Anesth. 2000 Feb; 12(1):40-7.
Eberhard LW, Morabito DJ, Matthay MA, Mackersie RC, Campbell AR, Marks JD, Alonso JA, Pittet JF. Initial severity of metabolic acidosis predicts the development of acute lung injury in severely traumatized patients. Crit Care Med. 2000 Jan; 28(1):125-31.
Amersdorfer P, Marks JD. Phage libraries for generation of anti-botulinum scFv antibodies. Methods Mol Biol. 2000; 145:219-40.
Cirino NM, Sblattero D, Allen D, Peterson SR, Marks JD, Jackson PJ, Bradbury A, Lehnert BE. Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors. Infect Immun. 1999 Jun; 67(6):2957-63.
Hughes-Jones NC, Bye JM, Gorick BD, Marks JD, Ouwehand WH. Synthesis of Rh Fv phage-antibodies using VH and VL germline genes. Br J Haematol. 1999 Jun; 105(3):811-6.
McCall AM, Adams GP, Amoroso AR, Nielsen UB, Zhang L, Horak E, Simmons H, Schier R, Marks JD, Weiner LM. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis. Mol Immunol. 1999 May; 36(7):433-45.
Poul MA, Marks JD. Targeted gene delivery to mammalian cells by filamentous bacteriophage. J Mol Biol. 1999 Apr 30; 288(2):203-11.
Becerril B, Poul MA, Marks JD. Toward selection of internalizing antibodies from phage libraries. Biochem Biophys Res Commun. 1999 Feb 16; 255(2):386-93.
McCall AM, Amoroso AR, Sautès C, Marks JD, Weiner LM. Characterization of anti-mouse Fc gamma RII single-chain Fv fragments derived from human phage display libraries. Immunotechnology. 1998 Jun; 4(1):71-87.
Sheets MD, Amersdorfer P, Finnern R, Sargent P, Lindquist E, Schier R, Hemingsen G, Wong C, Gerhart JC, Marks JD, Lindqvist E. Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc Natl Acad Sci U S A. 1998 May 26; 95(11):6157-62.
Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM, Marks JD. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer. 1998 May; 77(9):1405-12.
Cammarano WB, Pittet JF, Weitz S, Schlobohm RM, Marks JD. Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Crit Care Med. 1998 Apr; 26(4):676-84.
Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, Weiner LM. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res. 1998 Feb 01; 58(3):485-90.
Amersdorfer P, Wong C, Chen S, Smith T, Deshpande S, Sheridan R, Finnern R, Marks JD. Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries. Infect Immun. 1997 Sep; 65(9):3743-52.
Chen F, Kuziemko GM, Amersdorfer P, Wong C, Marks JD, Stevens RC. Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms. Infect Immun. 1997 May; 65(5):1626-30.
Finnern R, Pedrollo E, Fisch I, Wieslander J, Marks JD, Lockwood CM, Ouwehand WH. Human autoimmune anti-proteinase 3 scFv from a phage display library. Clin Exp Immunol. 1997 Feb; 107(2):269-81.
Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, Crawford RS, Weiner LM, Marks C, Marks JD. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol. 1996 Nov 08; 263(4):551-67.
Marks C, Marks JD. Phage libraries--a new route to clinically useful antibodies. N Engl J Med. 1996 Sep 05; 335(10):730-3.
Schier R, Balint RF, McCall A, Apell G, Larrick JW, Marks JD. Identification of functional and structural amino-acid residues by parsimonious mutagenesis. Gene. 1996 Mar 09; 169(2):147-55.
Schier R, Bye J, Apell G, McCall A, Adams GP, Malmqvist M, Weiner LM, Marks JD. Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection. J Mol Biol. 1996 Jan 12; 255(1):28-43.
Schier R, Marks JD. Efficient in vitro affinity maturation of phage antibodies using BIAcore guided selections. Hum Antibodies Hybridomas. 1996; 7(3):97-105.
Finnern R, Bye JM, Dolman KM, Zhao MH, Short A, Marks JD, Lockwood MC, Ouwehand WH. Molecular characteristics of anti-self antibody fragments against neutrophil cytoplasmic antigens from human V gene phage display libraries. Clin Exp Immunol. 1995 Dec; 102(3):566-74.
Schier R, Marks JD, Wolf EJ, Apell G, Wong C, McCartney JE, Bookman MA, Huston JS, Houston LL, Weiner LM. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology. 1995 May; 1(1):73-81.
Hughes-Jones NC, Gorick BD, Bye JM, Finnern R, Scott ML, Voak D, Marks JD, Ouwehand WH. Characterization of human blood group scFv antibodies derived from a V gene phage-display library. Br J Haematol. 1994 Sep; 88(1):180-6.
Figini M, Marks JD, Winter G, Griffiths AD. In vitro assembly of repertoires of antibody chains on the surface of phage by renaturation. J Mol Biol. 1994 May 27; 239(1):68-78.
Marks JD. Fiberoptic-aided endobronchial intubation. Int Anesthesiol Clin. 1994; 32(4):75-84.
Stackhouse RA, Marks JD, Bainton CR. Performing fiberoptic endotracheal intubation: clinical aspects. Int Anesthesiol Clin. 1994; 32(4):57-73.
Marks JD, Bainton CR. Practical aspects of fiberoptic laryngobronchoscopy. Int Anesthesiol Clin. 1994; 32(4):31-46.
Ouwehand WH, Bye JM, Gorick BD, Marks JD, Timmers E, Griffin HM, Finnern R, Hughes-Jones N. The humoral immune response against blood group antigens at the molecular level. Vox Sang. 1994; 67 Suppl 3:7-12.
Marks JD, Ouwehand WH, Bye JM, Finnern R, Gorick BD, Voak D, Thorpe SJ, Hughes-Jones NC, Winter G. Human antibody fragments specific for human blood group antigens from a phage display library. Biotechnology (N Y). 1993 Oct; 11(10):1145-9.
Griffiths AD, Malmqvist M, Marks JD, Bye JM, Embleton MJ, McCafferty J, Baier M, Holliger KP, Gorick BD, Hughes-Jones NC. Human anti-self antibodies with high specificity from phage display libraries. EMBO J. 1993 Feb; 12(2):725-34.
Hoogenboom HR, Marks JD, Griffiths AD, Winter G. Building antibodies from their genes. Immunol Rev. 1992 Dec; 130:41-68.
Bye JM, Carter C, Cui Y, Gorick BD, Songsivilai S, Winter G, Hughes-Jones NC, Marks JD. Germline variable region gene segment derivation of human monoclonal anti-Rh(D) antibodies. Evidence for affinity maturation by somatic hypermutation and repertoire shift. J Clin Invest. 1992 Dec; 90(6):2481-90.
Chothia C, Lesk AM, Gherardi E, Tomlinson IM, Walter G, Marks JD, Llewelyn MB, Winter G. Structural repertoire of the human VH segments. J Mol Biol. 1992 Oct 05; 227(3):799-817.
Tomlinson IM, Walter G, Marks JD, Llewelyn MB, Winter G. The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops. J Mol Biol. 1992 Oct 05; 227(3):776-98.
Marks JD, Hoogenboom HR, Griffiths AD, Winter G. Molecular evolution of proteins on filamentous phage. Mimicking the strategy of the immune system. J Biol Chem. 1992 Aug 15; 267(23):16007-10.
Marks JD, Griffiths AD, Malmqvist M, Clackson TP, Bye JM, Winter G. By-passing immunization: building high affinity human antibodies by chain shuffling. Biotechnology (N Y). 1992 Jul; 10(7):779-83.
Marks JD, Winter G. An artificial immune system for making antibodies. Behring Inst Mitt. 1992 Apr; (91):6-12.
Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol. 1991 Dec 05; 222(3):581-97.
Hastings RH, Marks JD. Airway management for trauma patients with potential cervical spine injuries. Anesth Analg. 1991 Oct; 73(4):471-82.
Marks JD, Tristem M, Karpas A, Winter G. Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family-specific oligonucleotide probes. Eur J Immunol. 1991 Apr; 21(4):985-91.
Songsivilai S, Bye JM, Marks JD, Hughes-Jones NC. Cloning and sequencing of human lambda immunoglobulin genes by the polymerase chain reaction. Eur J Immunol. 1990 Dec; 20(12):2661-6.
Biery DR, Marks JD, Schapera A, Autry M, Schlobohm RM, Katz JA. Factors affecting perioperative pulmonary function in acute respiratory failure. Chest. 1990 Dec; 98(6):1455-62.
Rubin DB, Wiener-Kronish JP, Murray JF, Green DR, Turner J, Luce JM, Montgomery AB, Marks JD, Matthay MA. Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome. J Clin Invest. 1990 Aug; 86(2):474-80.
Marks JD, Marks CB, Luce JM, Montgomery AB, Turner J, Metz CA, Murray JF. Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration. Am Rev Respir Dis. 1990 Jan; 141(1):94-7.
Schapera A, Marks JD, Minagi H, Goodman P, Katz JA. Perioperative pulmonary function in acute respiratory failure: effect of ventilator type and gas mixture. Anesthesiology. 1989 Sep; 71(3):396-402.
Marks JD, Schapera A, Kraemer RW, Katz JA. Pressure and flow limitations of anesthesia ventilators. Anesthesiology. 1989 Sep; 71(3):403-8.
Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis. 1988 Jul; 138(1):62-8.
Hansen RM, Viquerat CE, Matthay MA, Wiener-Kronish JP, DeMarco T, Bahtia S, Marks JD, Botvinick EH, Chatterjee K. Poor correlation between pulmonary arterial wedge pressure and left ventricular end-diastolic volume after coronary artery bypass graft surgery. Anesthesiology. 1986 Jun; 64(6):764-70.
Katz JA, Marks JD. Inspiratory work with and without continuous positive airway pressure in patients with acute respiratory failure. Anesthesiology. 1985 Dec; 63(6):598-607.
Marks JD, Luce JM, Lazar NM, Wu JN, Lipavsky A, Murray JF. Effect of increases in lung volume on clearance of aerosolized solute from human lungs. J Appl Physiol (1985). 1985 Oct; 59(4):1242-8.
MARKS JD, ROESKY N, CARVER MJ. The inhibitory action of a phenothiazine derivative on the hexosemonophosphate dehydrogenases of adrenal cortex. Arch Biochem Biophys. 1961 Nov; 95:192-6.